|
|
|
|
This is an archive page. The links are no longer being updated.
Testimony on National Institute of Neurological Disorders and Stroke's FY 1998 Budget by Dr. Zach W. Hall
Director, National Institute of Neurological Disorders and Stroke
National Institutes of Health
Accompanied by
Dr. Audrey S. Penn, Deputy Director, NINDS
Mr. Richard L. Sherbert, Executive Officer, NINDS
Mr. Andrew C. Baldus, Budget Officer, NINDS
and
Dr. Harold Varmus, Director, NIH
Mr. Dennis P. Williams, Deputy Assistant Secretary, Budget, DHHS
U.S. Department of Health and Human Services
Before the House Appropriations Committee, Subcommittee on Labor, Health and Human Services, Education and Related Agencies
March 5, 1997
Mr. Chairman and Committee Members:
Thank you for the opportunity to appear before this Committee. These appearances
are a pleasure for me because we are in an era of unprecedented progress in research on the
brain and its diseases, and I appreciate the opportunity to share with you some of the
important advances of the last year. There is a growing awareness of the importance of
diseases of the brain in our society. In part this arises because our population is aging, and
diseases of the brain become more prevalent as one gets older. In part it is also due to the
growing awareness of the importance of the nervous system for many problems that have
not traditionally been considered as biologically based diseases, conditions such as autism
or addiction or Tourette's syndrome. We share responsibility for brain research with a
number of other Institutes and Centers at NIH, and we cooperate with them in areas of
mutual research interest, including pain, sleep disorders, and neurological aspects of
AIDS. Our own Institute has responsibility for more than 600 neurological disorders,
ranging from those well-known, such as stroke, Parkinson's disease and epilepsy, affecting
millions of Americans, to those less common, such as Batten disease, Friedreich's ataxia
and ataxia-telangiectasia, that may affect a only few hundred Americans, but are
nevertheless devastating to the patients and their families.
These are exciting times in research on neurological disease, as we stand on the
threshold of an era in which the treatment of brain disease will become not just a promise,
but a reality. In the past, we have had few treatments to offer patients with brain disease.
When I was in medical school and became interested in neurological disease, I was told by
my advisors that if I was interested in the intellectual challenge of diagnosis, neurology
was a wonderful specialty, but if I wanted to make patients well, I should look for
something else. Fortunately, that distressing situation is about to change. As we make
progress in understanding the mechanisms at work in brain disease, as we identify genes
that cause or predispose to brain disease, as we understand more about how the normal
brain works, we are better able to devise treatments to prevent, slow or stop the disease
process. Today, I want to tell you about our progress in three important disease areas:
stroke, Parkinson's disease and spinal cord injury.
Stroke
Stroke is a major health problem in the United States; 500,000 Americans have a
stroke each year; of these approximately 150,000 die. Those who survive are often left
with major disability, at great emotional and financial cost to their families and to our
society. Last year at this time I reported that NINDS, working with leading investigators
across the country, with the private sector, and with the patient community, had organized
a clinical trial showing for the first time that prompt administration of a clot-buster to
those with the most common form of stroke gives a 30% increase in the chance for full
recovery. This finding heralds a new era in stroke medicine, by showing that acute
treatment can be effective. Widespread use of the new treatment will not follow
automatically, however, because to be effective, therapy must be delivered within three
hours after symptoms first appear. To insure such prompt treatment requires that
physicians, patients and their families be educated, and that paramedics and hospital
personnel be organized to give urgent care. Our clinical trial provided a model for this
change by showing that a rapid response could be organized in a variety of health care and
emergency settings. To help bring about the change, NINDS convened a major
symposium involving doctors, nurses, paramedics, and patient representatives, to provide
guidance for health care providers implementing acute stroke therapy. We will continue to
work with patient and professional organizations to publicize the results of the
symposium, helping public and health care professionals organize acute stroke treatment
in a variety of settings.
Parkinson's Disease
Parkinson's disease (PD), which usually strikes in late middle age and affects more
than a half million Americans, impairs control of movement, progressing from symptoms
such as tremor and muscular rigidity to total disability and death. Parkinson's disease, like
Alzheimer's disease, amyotrophic lateral sclerosis (ALS), and Huntington's disease, is a
neurodegenerative disease with an unknown cause.
- In 1995 NINDS and three other institutes sponsored a Parkinson's Disease Research
Planning Workshop to identify new directions of research. A major conclusion of the
Workshop was that PD likely has a large genetic component. In response, NINDS
initiated a collaboration with the National Human Genome Research Institute and
extramural researchers which quickly showed that in a single large family PD was caused
by an alteration in a gene on chromosome 4. This discovery was published in last
November's issue of the journal, Science. Current investigations are aimed at identifying
the gene and determining whether genetic alterations would benefit patients. Most
importantly, identification of the genes responsible for familial Parkinson's disease may
help solve the mystery of what triggers the degenerative processes in both familial and
non-familial Parkinson's disease and provides the tools for testing new treatments. As a
result of the 1995 Workshop, NINDS also issued a program announcement calling for
applications on the mechanisms of cell death and injury in neurodegenerative disorders
including PD, jointly sponsored by the National Institute on Aging, the National Institute
of Environmental Health Sciences, and the National Institute of Mental Health.
- Clinical trials are underway to evaluate a surgical technique called pallidotomy to
treat PD. Other trials are investigating the use of nervous system tissue implanted into the
brain to halt or delay the process of degeneration, and to evaluate improved drug therapy
for people with advanced PD.
- Trophic, or nurturing, factors are important for the survival of neurons in the
growing brain and are essential for a healthy nervous system in adults. Promising results
using trophic factors as therapies for PD have now been extended to primate models.
Further research is required to overcome obstacles to human administration.
Spinal Cord Injury
One reason trauma to the central nervous system has such severe consequences is
that neurons in the brain and spinal cord fail to regenerate after damage. Now we know
they make unsuccessful attempts to regenerate, and in some circumstances can be coaxed
to regrow. In 1996, NINDS with other NIH components sponsored a major workshop to
foster new ideas and collaborations. Following that meeting, NINDS issued a program
announcement to encourage research in several areas with potential for success:
- Neuroprosthetic devices connect with the nervous system via electrodes to stimulate
muscles or provide sensory input. For example, a neural prosthesis developed with
NINDS support and recently recommended for approval by an FDA advisory panel
restores significant hand function to quadriplegics. Realistic future targets include a
splint-free system to allow a paraplegic person to rise, stand, and sit again without
assistance, and technologies to control muscles using direct brain signals.
- High dose methylprednisolone, the first therapy to improve the outcome of spinal
cord injury, is now regularly used in emergency rooms. The effects of longer
methyl-prednisolone treatment and of a new class of cortico-steroid drugs are now being studied.
- Efforts to repair damaged spinal cords in animals are continuing, using grafts,
nerve bridges, cell implants, cell survival factors, antibodies, and genetic engineering. An
NINDS grantee in Sweden has been able to use nerve grafts successfully in animals to
bridge gaps in injured spinal cords. The potential use of newly-discovered neural
progenitor cells, nerve cells that may have the capacity to replace cells lost because of
trauma, is also under investigation.
Diseases of Childhood
More than a third of all genetic disorders affect the nervous system, and hundreds
affect infants and children. In the past several years, research has rapidly progressed in
identifying genes for a number of brain disorders. Approximately 50 genes have been
identified. Finding the defective gene that causes a disease is only a beginning towards
developing a therapy, but it allows scientists to develop diagnostic tests, create animal
models, learn how the gene and its protein function to promote health or disease, and
pursue a reasoned strategy towards counteracting the defect. Examples of progress in
understanding neurogenetic disorders of infancy and childhood include:
- In neurofibromatosis 1, a common hereditary disorder of the nervous system,
tumors, called neurofibromas, develop along nerves. Most of these tumors are benign but
some become malignant. A defective NF1 gene results in the disease, and the normal gene
is thought to be a tumor suppressor. This is an important clue to tumor formation in NF
and perhaps will help predict which tumors will progress to malignancy, a valuable tool
for planning surgery or other treatments.
- Recently scientists discovered that a defect in a gene for a previously unknown
protein causes Friedreich's ataxia, a neurodegenerative disease of childhood. This should
lead to a test for screening carriers of the gene and also to effective treatments.
- Turner syndrome, a genetic disorder of the X chromosome causing a lack of sexual
development and a variety of cognitive and motor deficiencies, occurs in about 1 of every
3000 live-born females. Ongoing clinical trials are examining the effects of estrogen and
androgen on cognition and social development. Besides providing information about the
effectiveness of hormone replacement therapies for girls with Turner syndrome, these
studies present a unique opportunity to study the effects of hormones on brain
development and function, with implications for children's and women's health.
Last year we reported exciting evidence that the administration of magnesium
sulfate to mothers at risk for premature delivery was associated with a reduced risk of
cerebral palsy in their infants. Now, NINDS is collaborating with the National Institute of
Child Health and Human Development on a prospective clinical trial designed to validate
this finding. In another study published in 1996, NINDS-funded researchers linked low
levels of the hormone thyroxin in premature infants to cerebral palsy, suggesting another
avenue for preventing this disabling illness.
Future Research
Despite the astonishing progress of neuroscience, there is much we do not
understand about the brain. Continued support of fundamental neuroscience research will
undoubtedly yield important insights. Progress in molecular biology, genetics, imaging,
and other areas has accelerated the flow of knowledge between basic and clinical
neuroscience. NINDS is taking steps to enhance the Institute's ability to respond to
emerging clinical research opportunities. While relying primarily on investigator-initiated
ideas and peer review to ensure the best quality science, the Institute uses other important
tools for stimulating research. In FY 1996 NINDS solicited new research proposals from
extramural investigators in the genetics of Parkinson's disease, mechanisms of cell death
and injury in neurodegenerative disorders, Batten disease, immune system mediated
diseases, central nervous system injury, and the effect of HIV in the brain. NINDS
additionally organizes and funds workshops either directly, as in the case of recent
workshops on Parkinson's disease and spinal cord injury, or through grants to
investigators or organizations. The Institute will continue to take appropriate active steps
to stimulate submission of research ideas in areas identified as high priority and to
participate in the NIH special emphasis areas: Biology of Brain Disorders, Preventive
Strategies, Therapeutics/Drug Development, and Genetics of Medicine.
Mr. Chairman, the FY 1998 budget request for this Institute is $722,712,000. I
would be pleased to answer any questions you might have.
Privacy Notice (www.hhs.gov/Privacy.html) |
FOIA (www.hhs.gov/foia/) |
What's New (www.hhs.gov/about/index.html#topiclist) |
FAQs (answers.hhs.gov) |
Reading Room (www.hhs.gov/read/) |
Site Info (www.hhs.gov/SiteMap.html)
|
|
|